1. Ayaki, M., Iwasawa, A., and Inoue, Y. (2010) Toxicity to human corneal endothelial cells of major antiglaucoma medications with and without benzalkonium chloride. Clinical Ophthalmology, 4, 1217-1222.
2. Ayaki, M., and Iwasawa, A. (2011b) Critical concentration of benzalkonium chloride in eye drop for toxicity in cultured ocular surface cell lines. Inv. Ophthalmol. Vis. Sci., 52, E-Abstract 1955.
3. Preservatives in eyedrops: The good, the bad and the ugly
4. Boyle, J.E., Ghosh, K., Gieser, D.K., and Adamsons, I.A. (1998) A randomized trial comparing the dorzolamide/timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology, 105, 1945-1951.
5. Fechtner, R.D., Airaksinen, P.J., Getson, A.J., Lines, C.R., and Adamsons, I.A. (2004) COSOPT versus XALATAN Study Groups. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol. Scand., 82, 42-48.